Personally I wouldn't do methionine restriction, because eventually it results in similar, maybe slightly less, restricted growth as with CR, but the long term side-effects are a big unknown.
Looks like the only solution is protein restriction, which in my opinion is a dicey thing if you want to maintain lean body mass.
No creative work arounds possible? Do you think methionine degrading enzymes might work (thanks to aidanpryde for bringing this up in one of our discussions)?
I guess the only problem would be their cost and availability or maybe dose and delivery. Would you add the enzyme to your food, ingest it or deliver it via s.c. injection?
Recombinant methioninase (rMETase) is being tested as a cancer treatment. Price, however, could be very high, because rMETase has 398 amino acid residues per subunit [3] and consists of 4 subunits (insanely expensive hGH has "only" 191 to give you an idea).
Maybe you could contact some supliers if you want to find out more about costs, if the idea has any merit that is. They sell the enzyme in units. So how many units do we need? All tests seem to be done in nude mice:
"rMETase at 15 units/g/day for 5 days depleted tumor methionine in all four tumor types to approximately 30% of untreated control." [1]
"A single i.p. injection of 300 units of rMETase can lower the serum methionine level in the mice from 70 microM to less than 1 microM within 2 h and maintain this depleted level for 8 h." [2]
PEGylated rMETase may be a solution:
"Plasma
methionine was depleted from a baseline of 40 µM to less than 5 µM within 1 h by 80 U naked and the three PEGylated conjugates (Fig. 5) . However, PEG/rMETase-30, PEG/rMETase-60 and PEG/rMETase-120 depleted the plasma methionine level below 5 µM for 8, 24, and 48 h, respectively, which is 2-, 6-, and 12-fold longer than naked rMETase (Table 2B)" [3]
Suppliers I have come up with via google:
A.
http://www.biocompar...ecombinant.htmlB.
http://www.bioresear...1?VNETCOOKIE=NOJust one of the many articles on cancer and methioninase:
Bull Cancer. 2008 Jan;95(1):69-76.
[Methionine dependency of cancer cells: a new therapeutic approach?]
Durando X, Thivat E, Gimbergues P, Cellarier E, Abrial C, Dib M, Tacca O, Chollet P.
Département d'oncologie médicale, Centre Jean Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France.
Metabolic abnormalities of tumor cells offer opportunities of therapeutic targeting. In contrast to normal cells, tumor cells have absolute requirement for methionine (Met), an essential amino acid. Many molecular mechanisms have been considered to explain Met dependency. Several approaches have been used To reduce Met in vivo. As the main Met source was food, synthetic Met free diet were widely used. Alternatively, Met restriction was archived by the use of Met analogs or enzymatic degradation by methioninase. In animal models, Met restriction permit to limit tumor growth and to reduce tumor volume. However, interruption of Met restriction induce the regrowth of tumor. Moreover Met restriction induce several cells modifications suggesting its use in association with conventional chemotherapy. Preclinical studies have shown synergistic effect of the association of Met restriction and different cytostatic agents. Currently, few clinical investigations have been realised to test this therapeutic strategy.
[1] Clin Cancer Res. 1999 Aug;5(8):2157-63.
Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX, Hoffman RM.
[2] Cancer Res. 1998 Jun 15;58(12):2583-7.
Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.
Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM, Sugita K.
[3] In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5'-Phosphate Supplementation
Full:
http://cancerres.aac...full/63/23/8377
Edited by kismet, 25 December 2008 - 08:13 PM.